| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/23/2023 |
8-K/A
| Investor presentation |
| 08/21/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 08/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/21/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/13/2023 |
4
| KLEMP WALTER V (CEO and President) has filed a Form 4 on Moleculin Biotech, Inc.|
Txns:
| Paid exercise price by delivering 3,216 shares
@ $0.5903, valued at
$1.9k
Exercised 13,204 restricted stock units
@ $0 |
|
| 07/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/05/2023 |
4
| KLEMP WALTER V (CEO and President) has filed a Form 4 on Moleculin Biotech, Inc.|
Txns:
| Paid exercise price by delivering 3,584 shares
@ $0.5788, valued at
$2.1k
Exercised 14,717 restricted stock units
@ $0 |
|
| 06/16/2023 |
8-K/A
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/26/2023 |
4
| Yan Joy (Director) has filed a Form 4 on Moleculin Biotech, Inc.|
Txns:
| Granted 15,000 options to buy
@ $0.62, valued at
$9.3k
|
|
| 05/26/2023 |
4
| Cermak Elizabeth (Director) has filed a Form 4 on Moleculin Biotech, Inc.|
Txns:
| Granted 15,000 options to buy
@ $0.62, valued at
$9.3k
|
|
| 05/26/2023 |
4
| Climaco John M (Director) has filed a Form 4 on Moleculin Biotech, Inc.|
Txns:
| Granted 15,000 options to buy
@ $0.62, valued at
$9.3k
|
|
| 05/26/2023 |
4
| CANNON MICHAEL D (Director) has filed a Form 4 on Moleculin Biotech, Inc.|
Txns:
| Granted 15,000 options to buy
@ $0.62, valued at
$9.3k
|
|
| 05/26/2023 |
4
| George Robert E. (Director) has filed a Form 4 on Moleculin Biotech, Inc.|
Txns:
| Granted 15,000 options to buy
@ $0.62, valued at
$9.3k
|
|
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/12/2023 |
8-K
| Investor presentation |
| 05/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|